Today: December 14, 2018, 5:23 am

Primary Sclerosing Cholangitis Market to Reach US$ 140.4 Million by 2023

Coherent Market Insights Logo
Coherent Market Insights Logo
Primary Sclerosing Cholangitis Market has potential pipeline products and is estimated to reach US$ 140.4 Mn by 2023, as highlighted in a new report published by Coherent Market Insights. 2018-07-31 15:42:27
(EMAILWIRE.COM, July 30, 2018 ) Global Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) has potential pipeline products and is estimated to reach US$ 140.4 Mn by 2023, as highlighted in a new report published by Coherent Market Insights.

Pharmaceutical companies are focusing on enhancing research and development for introducing novel therapeutics to address unmet patient needs. For instance, the discovery and development of siRNA (small interfering RNA) therapeutics by Sirnaomics, Inc., with dual-target properties and polypeptide nanoparticle (PNP)-enhanced delivery that directly controls the fibrotic and inflammatory activity is expected to have wide applications in many inflammatory and fibrotic diseases.

The support from public and private organizations such as PSC Support Organization and National Organization for Rare Disorders serves as the hub of rare disease community, providing assistance programs for patients and advancing clinical trials by granting funds for advanced research programs. The UK PSC Support Organization granted US$ 20,000 to the University of Birmingham for supporting the research and investigation of Vascular Adhesion Protein (VAP-1) in primary sclerosing cholangitis (PSC). Also, in 2017, the Falk Foundation funded a European multi-center phase II study led by the Medical University of Vienna in collaboration with the Medical University of Graz and the Medical University of Hannover, to treat primary sclerosing cholangitis.

Browse through 134 Pages and an in-depth TOC on Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

Latest trends and insights prevalent in the primary sclerosing cholangitis market: ..

Orphan drug designation granted by regulatory agencies such as the Food and Drug Administration (FDA) and European Medicine Agency (EMA) for the treatment of PSC enables manufacturers to accelerate drug development process for providing new drug treatments to patients in need. For instance, in 2017, Conatus Pharmaceuticals Inc. was granted orphan designation to IDN-7314 by the FDA and EMA. The drug completed two successful pre-clinical trials, of which the second one was completed in 2017. Also, in 2016, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for BTT1023 drug candidate developed by Acorda Therapeutics, which is in Phase 2 clinical trials currently.

Also, pharmaceuticals companies are focusing on mergers and acquisitions to accelerate the development of new treatment options to address the unmet needs of patients suffering from rare diseases by advancing the therapies into clinical trials. For instance, in 2015, Gilead Sciences, Inc. acquired Phenex Pharmaceuticals AG, to gain access to Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including PSC and nonalcoholic steatohepatitis (NASH). Also, in February, 2018, Intercept Pharmaceuticals, Inc. collaborated with Sumitomo Dainippon Pharma Co. Ltd., to develop and commercialize Obeticholic Acid (OCA) for chronic liver disease in Japan, China, and Korea.

In 2014, Shire acquired Lumena Pharmaceuticals, to gain access to its late stage rare disease pipeline assets indicated for gastrointestinal conditions- LUM001 and LUM002, thus providing potential treatment options to patients with rare cholestatic liver disease and adding products to its rare disease portfolio.

Click here to buy this Market Intelligence Report:

Click the Link below to have a look at a Sample before buying

Request Sample:

Key Takeaways of the Primary Sclerosing Cholangitis Market:

According to the Research Institute of Radiological Science, 2016, the prevalence of PSC is higher in Northern Europe and the U.S. around 10 per 100,000 population, while it is far less common in Southern Europe and Asia

Requirement of providing affordable treatment, owing to high costs associated with liver transplantation coupled with increasing risk factors resulting in the development of serious disorders are factors that are expected to bolster market growth in the near future.

Some of the major players operating in the global primary sclerosing cholangitis market include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,


Seattle, WA 98154

Tel: +1-206-701-6702


This is a press release. Press release distribution and press release services by EmailWire.Com:

Press Information

Published by
GroupWeb EmailWire.Com

# 794 Words
Related Articles
More From The Author
Picture Archiving and Communication System (PACS) Market [..]
(EMAILWIRE.COM, July 30, 2018 ) The Global Picture Archiving and Communication System (PACS) Market, by Deployment (Web Based, [..]
Electroceutical Devices Market to Surpass US$ 33 [..]
(EMAILWIRE.COM, July 30, 2018 ) The Global Electroceutical Devices Market, by Product (Cardiac Pacemakers, Implantable Cardioverter Defibrillators, [..]
Smart Healthcare Products Market is Expected to [..]
(EMAILWIRE.COM, July 23, 2018 ) The Global Smart Healthcare Products Market, by Product Type (Electronic Health Record, Smart [..]
Complex Fertilizers Market to Surpass US$ 75,698.5 [..]
(EMAILWIRE.COM, July 23, 2018 ) Major factors propelling growth of the global complex fertilizers market include favorable growth [..]
(EMAILWIRE.COM, April 09, 2018 ) Birmingham, AL -- If life were akin to having a meal at a fine dining [..]
More From Health
Over 2025, The Global HPMC Capsules Market [..]
HPMC capsules are strictly non-toxic and qualify to be Kosher and Halal-certified, which is why their popularity has grown in [..]
Indiva åbner vejen til det europæiske cannabismarked [..]
Aftalen omfatter en licens til 100% overtagelse af dyrkning og ekspedition af cannabis til medicinske formål under Lægemiddelstyrelsens udviklingsprogram. [..]
Breathe easy at home with Blueair’s revolutionary [..]
Dubai UAE, November 29, 2018: According to a recent report by the World Health Organisation (WHO) nine in ten people [..]
5 Growth Hacks to Increase Followers on [..]
22 November 2018 – Medium has posted an article in which there is a description of five important tips on [..]
Middle East Organic & Natural Products Expo [..]
The Middle East Organic & Natural Products Expo 2018 is returning to Dubai Convention & Exhibition Centre on November 18-20. [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.